



Q2 2026

Earnings Call Presentation

August | 2026

Disclaimer

This presentation has been prepared by Auna S.A. ("Auna" or the "Company") solely for use at this presentation.

This presentation contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to differ materially from the forward-looking statements that we make. Forward-looking statements typically are identified by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "project," "plan," "believe," "potential," "continue," "is/are likely to," or other similar expressions. Forward-looking statements that appear in a number of places in this presentation include, but are not limited to, statements regarding the intent, belief or current expectations, regarding various matters, including, our target Leverage Ratio, the results of the key initiatives we are implementing in Mexico, Colombia and Peru, the expected capacity and market of Torre Trecca once built, the execution of our strategic plan, including the recovery of our growth levels and the roll-out of the AunaWay in Mexico, our planned investments, expected revenue and Adjusted EBITDA growth, our revenue and Adjusted EBITDA guidance, and the creation of further growth and sustainable value for all stakeholders. Any or all of our forward-looking statements in this presentation may turn out to be inaccurate. Our actual results could differ materially from those contained in forward-looking statements due to a number of factors.

The forward-looking statements in this presentation represent our expectations and forecasts as of the date of this presentation. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this presentation. For a discussion of the risks facing the Company which could affect whether these forward-looking statements are realized, see our Form 20-F filing with the U.S. Securities and Exchange Commission.

No representations or warranties, express or implied, are made as to, and no reliance should be placed on, the accuracy, fairness or completeness of the information presented or contained in this presentation. Neither the Company nor any of its affiliates, advisers or representatives or any of their respective affiliates, advisers or representatives, accepts any responsibility whatsoever for any loss or damage arising from any information presented or contained in this presentation. The information presented or contained in this presentation is current as of the date hereof and is subject to change without notice and its accuracy is not guaranteed. Neither the Company nor any of its affiliates, advisers or representatives make any undertaking to update any such information subsequent to the date hereof. This presentation should not be construed as legal, tax, investment or other advice.

In addition to IFRS financials, this presentation includes certain non-IFRS financial measures. These non-IFRS financial measures are in addition to, and not a substitute for, measures of financial performance prepared in accordance with IFRS. For a description and a reconciliation of these non-IFRS financial measures to the corresponding nearest IFRS measure, please see the exhibit to this presentation.

Certain data in this presentation was obtained from various external data sources, and the Company has not verified such data with independent sources. Certain data was also based on the Company's estimates. Accordingly, the Company makes no representations as to the accuracy or completeness of that data or the Company's estimates, and such data and estimates involve risks and uncertainties and are subject to change based on various factors. The 2026 financial guidance reflects management's current assumptions regarding numerous evolving factors that are difficult to accurately predict, including those discussed in the risk factors set forth in the Company's Form 20F filed with the U.S. Securities and Exchange Commission. Reconciliations of forward looking non-IFRS measures, specifically the 2026 EBITDA Guidance, to the relevant forward-looking IFRS measures are not being provided, as the Company currently does not have sufficient data to accurately estimate the variables and individual adjustments for such variance and reconciliations. Due to this uncertainty, the Company cannot reconcile projected Adjusted EBITDA to projected Net income without unreasonable effort. The 2026 financial guidance constitutes forward-looking statements.

Today's Speakers



Jesus Zamora

Executive Chairman of the Board and President



- Member of the Board since 2008 and President since 2023
- Founder and Chairman of the Board at Enfoca
- MBA from Columbia Business School and a B.S. in Industrial Engineering from Universidad Nacional Autónoma de México

Years of experience



Gisele Remy

Chief Financial Officer and Executive Vice President



- Chief Financial Officer since 2023
- Previously Managing Director of Finance and Productivity at Alicorp and Director of Strategy and Treasury at Belcorp
- B.S. in Business Administration with concentration in Finance from the Wharton School of the University of Pennsylvania



Lorenzo Massart

Executive Vice President, Strategy and Equity Capital Markets



- EVP, Strategy and Equity Capital Markets since 2024
- Previously at Enfoca, Citi, Bank of America, Morgan Stanley and McKinsey
- Master in Business Administration from the Wharton School of the University of Pennsylvania and B.S. and M.S. from HEC Lausanne

2Q'26 Highlights

Consolidated Revenues¹ +9% FXN YoY vs 2Q'25 with revenue increases across all business segments.

Adjusted EBITDA^{1,2} -9% FXN YoY with 18.4% margin, -3.7p.p. vs 2Q'25; **+3% FXN QoQ** with flat margin growth.

Mexico's volume recovery accelerated through 2Q26 driven by improved payor tiering, favorable pricing in high-complexity care, improved economics from ISSTELEON and expanding oncology offerings. **Healthcare Services revenue in Monterrey +5% QoQ.**

Peru revenues +8% on increased ticket and memberships, and increased focus on high complexity surgeries in the healthcare network.

Colombia increased volumes and capacity versus 2Q25 and 1Q26. **Adjusted EBITDA +18% QoQ.**

Leverage Ratio² **stable at 3.6x**, down from 3.7x in 1Q26

End of period Cash increased 43% versus YE 2025; Free Cash Flow increased 181% YoY, demonstrating effective cash management across the regional platform.

Notes: Reported results impacted by depreciation of PEN/MXN (5%) and depreciation of PEN/COP (9%) YoY. 1. As reported, 2Q26 Revenues increased 13% YoY to S/1,238 and Adjusted EBITDA decreased 6% YoY to S/227 million. 2. Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Leverage Ratio and FX Neutral ("FNX") are non-IFRS financial measures. For a description and a reconciliation of these non-IFRS financial measures to the corresponding nearest IFRS measure, please see the exhibit to this presentation.

“The second quarter demonstrated clear progress in our operational performance, despite temporary margin pressures across the business.”

Strong top line across all segments and robust cash flow generation

Consolidated Adjusted EBITDA impacted by service mix, temporary cost pressures and billing penalties

Consolidated 2Q26



Revenue (\$/)

1,238Mn

+13% YoY

+9% FXN YoY



Adjusted EBITDA⁽¹⁾ (\$/)

227 Mn

-6% YoY

-9% FXN YoY

Healthcare Services

Oncosalud Peru

Cash Flow



Bed capacity ⁽²⁾

2,337

beds



Total Capacity Utilization

66%

+2.3 p.p. YoY



Plan Memberships

1,472,019

+6% YoY



Oncology Memberships

1,004,782

1% YoY



Oncology MLR

50.1%

0.3 p.p. YoY



Free Cash Flow ⁽¹⁾

402 Mn

+1.8x YoY

Notes: 1. Adjusted EBITDA and Free Cash Flow are non-IFRS financial measures. For a description and a reconciliation of non-IFRS financial measures to the corresponding nearest IFRS measure, please see the exhibit to this presentation. 2. Includes all beds within the Healthcare Network and 109 Oncology beds.


Q2 2026 Results by Segment






Healthcare Services Mexico grows revenues YoY. QoQ revenues grew from 2026 initiatives executed in the network, including doctor onboarding, tier upgrades and oncology volumes. Revenue and Adjusted EBITDA increased sequentially by 5% and 3%, respectively.

External Revenue¹ (\$/ Mn, %)
24% of LTM Revenues




Adj. EBITDA and margin^{1,2} (\$/ Mn, %)
32% of LTM Adj. EBITDA



Peru revenue growth from higher Oncosalud pricing and B2B memberships and HC network focus on high complexity. Adj. EBITDA negatively impacted by accepted penalties from reconciliation of prior years' receivables.


External Revenue¹ (\$/ Mn, %)

43 % of LTM Revenues



Adj. EBITDA and margin^{1,2} (\$/ Mn, %)

47% of LTM Adj. EBITDA






Colombia expands risk sharing agreements (“PGPs”) and improves payment terms.
YoY Adjusted EBITDA impacted by higher variable costs and statutory wage increases, which we expect to be offset by price adjustments in the 2H as we continue to stabilize PGPs.


External Revenue¹ (\$/ Mn, %)

34% of LTM Revenues



Adj. EBITDA and margin^{1,2} (\$/ Mn, %)

23% of LTM Adj. EBITDA



Q2 2026 Consolidated Results




aina

Strategic initiatives executed across all segments result in sustained revenue growth

- Mexico increased YoY volumes: +6% in surgery and +86% in oncology with operating utilization of 49.9%, +6.0 p.p.
- Peru adds 7,000 memberships through B2B; the HC network increased high complexity surgery volumes.
- In Colombia, new payors replaced revenues from government intervened payors; revenues from private payors, +17% YoY, representing 18% of segment revenues.

External Revenue

(S/ Mn, %)




Consolidated Adjusted EBITDA reflects temporary margin pressures from service mix, pharmacy and payroll costs, as well as, the impact of accepted penalties from reconciliation of prior years' receivables.

- PEN/MXN depreciation of 5% and PEN/COP depreciation of 9% YoY.

Adjusted EBITDA¹ Bridge 2Q'26 vs 2Q'25

(\$/ Mn, %)

Adjusted
EBITDA
Margin¹




Notes: 1. Adjusted EBITDA and Adjusted EBITDA Margin are non IFRS measures. For a description and reconciliation to the nearest IFRS measure, see the exhibit to this presentation.

Adjusted Net Income of S/40 million, on lower FX gain and operating profit, partially offset by lower net interest expenses and improved income tax efficiencies.

- Lower non-cash FX gains mainly due to the depreciation of the Peruvian Sol below the protection range of Auna's new hedging structure implemented at the end of 2025 to reset the call-spread levels and better align them with the prevailing USD/PEN exchange rate to reduce future P&L volatility.

Adjusted Net Income¹ bridge: 2Q'26 vs 2Q'25

(S/ Mn)




Notes: 1. Adjusted Net Income is a non IFRS measure. For a description and reconciliation to the nearest IFRS measure, see the exhibit to this presentation. 2. Adjusted Basic and Diluted Earnings per Share is a non IFRS measure. For a description and reconciliation to the nearest IFRS measure, see the exhibit to this presentation. 3. Includes Share of profit from equity-accounted investees.

Free Cash Flow generation expands 181% versus 2Q25 off the back of working capital discipline and supplier financing initiatives. EoP cash grows 43% versus year-end 2025.

- Free cash flow includes Maintenance CapEx of S/65 million, or 3% of revenues
- On track to achieve 3.0x medium term leverage target

Cash flow bridge

(S/ Mn)




Leverage ratio improved QoQ on lower gross debt and improved EoP cash

Debt Structure Highlights


- ✓ Committed to achieving 3.0x Leverage Ratio target.
- ✓ Gross Debt decreased by PEN 43 million on a FX-neutral basis as of 2Q26. However, the depreciation of the Peruvian sol against the Mexican peso and U.S. dollar masked this underlying improvement, resulting in reported debt increasing by PEN 74 million vs. 4Q25.
- ✓ Q2 Short- Term Lines: \$190.6M total (\$65.4M /34% utilized; \$125.2M available)
- ✓ 56% of debt in direct local currency funding and remaining US\$ denominated debt is 85% hedged to PEN. 75% of MXN TIE floating interest rate debt also hedged.

Leverage Ratio¹




Debt by Type (%)

Consolidated Debt: S/3,730




Debt by Currency (%)



Debt Amortization Profile^{2,3} (S/ MM)

2Q26 Gross Debt Balance: S/3,730 (US\$ 1,094 MM)



Sources: Company financial information

Notes: Considers an exchange rate of S/3.4100 to US\$1.00. 1. Leverage Ratio is a non IFRS measure. For a description and reconciliation to the nearest IFRS measure, see the exhibit to this presentation. 2. Excludes interest. Y1 = July 2026 to June 2027, Y2 = July 2027 to June 2028, Y3 = July 2028 to June 2029, Y4 = July 2029 to June 2030, Y5 = July 2030 to June 2031, and Y6+ = July 2031 to September 2035.. 3. Year 1 maturities include S/ 229M (US\$ 67 M) related to working capital facilities, which are expected to be renewed in the ordinary course of business.

“We are reaffirming our full-year 2026 revenue guidance at the midpoint of the range and Adjusted EBITDA guidance at the low end of the range, excluding the billing impacts in Peru”

Peru continues demonstrating the success of Auna’s vertically integrated model at scale. The healthcare services network will continue prioritizing high-complexity surgical procedures, while Oncosalud profitability should improve as onboarding from new B2B accounts normalizes. Strategic, asset-light investments, including the Versius SP4 Robotic system and our Lima Sur expansion, further strengthen our competitive position.

Colombia will resume margin growth in 2H as contractual price adjustments take full effect to offset first-half statutory wage increases, alongside further scaling of predictable PGP risk-sharing models. The capacity expansion in Montería is expected to be accretive through the remainder of the year.

Mexico’s healthcare network continues delivering sequential growth. Improved payor tier classifications, onboarding of physicians, and oncology expansion position the network for sustained second half volume growth. The new linear accelerator will strengthen our clinical capabilities and operating efficiencies.

Free Cash Flow is expected to exceed original internal expectations driven by disciplined working capital management and improved collections, further supporting our path toward a leverage ratio below 3.0x.

We are reaffirming our full-year 2026 guidance with revenue growth of approximately 12%, and with Adjusted EBITDA trending toward the low end of the 10%–14% range (excluding the impacts of billing in Peru). We are confident in these targets, supported by Mexico’s strong volume recovery and expected performance in Peru and Colombia.

Q&A



aluna

Exhibits



Consolidated Balance Sheet

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	Jun-26 (USD)	Jun-26	Dec-25	Δ Jun-26 vs Dec-25		Jun-26 (USD)	Jun-26	Dec-25	Δ Jun-26 vs Dec-25
Assets					Liabilities				
Current assets					Current liabilities				
Cash and cash equivalents	140	478	335	142	Loans and borrowings	117	399	316	83
Trade accounts receivable	333	1,137	1,043	94	Lease liabilities	9	31	29	2
Other assets	78	266	259	8	Trade accounts payable	336	1,147	1,053	94
Inventories	44	149	165	(16)	Other accounts payable	76	259	225	33
Insurance contract assets	2	8	13	(5)	Provisions	3	12	10	1
Other investments	1	3	30	(27)	Derivative financial instruments	10	35	23	12
Total current assets	599	2,042	1,845	197	Insurance contract liabilities	5	15	9	6
Non-current assets					Deferred income	0	0	0	0
Trade accounts receivable	0	0	0	(0)	Total current liabilities	557	1,898	1,667	231
Other assets	8	28	27	1	Non-current liabilities				
Investments in associates and joint venture	10	34	30	4	Loans and borrowings	941	3,207	3,216	(9)
Property furniture and equipment	702	2,394	2,287	107	Lease liabilities	27	92	94	(2)
Intangible assets	837	2,855	2,704	151	Trade accounts payable	0	1	1	(1)
Right-of-use assets	33	114	113	0	Other accounts payable	67	230	222	8
Investment properties	2	7	6	0	Derivative financial instruments	9	31	40	(9)
Derivative financial instruments	16	54	54	(0)	Deferred tax liabilities	83	284	291	(7)
Deferred tax assets	79	268	231	37	Deferred income	0	0	0	(0)
Other investments	0	0	1	(0)	Total non-current liabilities	1,128	3,846	3,865	(19)
Total non-current assets	1,687	5,754	5,454	300	Total liabilities	1,684	5,744	5,532	212
Total assets	2,286	7,796	7,298	498	Total equity	602	2,052	1,766	286
					Total liabilities and equity	2,286	7,796	7,298	498

Consolidated Statement of Income (1/2)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	2Q'26 (USD)	2Q'26	YTD 26	Δ 2Q'26 vs 2Q'25	Δ YTD 26 vs YTD 25
Revenue					
Healthcare Services Mexico	88	300	579	10%	12%
Healthcare Services Colombia	125	426	824	23%	20%
- Healthcare Services Colombia	125	427	827	23%	21%
- Holding and eliminations	(0)	(1)	(3)	-	-
Healthcare Services Peru & Oncosalud Peru	150	512	1,012	8%	8%
- Healthcare Services Peru	87	296	578	10%	8%
- Oncosalud Peru	93	317	631	11%	11%
- Holding and eliminations	(30)	(101)	(196)	25%	19%
Total Revenue	363	1,238	2,416	13%	13%
Cost of sales and services	(233)	(796)	(1,542)	21%	17%
Gross profit	130	442	873	2%	7%
Gross margin		35.7%	36.2%	-4.0 p.p.	-2.1 p.p.
Selling expenses	(18)	(62)	(124)	14%	15%
Administrative expenses	(68)	(232)	(446)	11%	14%
(Loss) reversal for impairment of trade receivables	0	0	(8)	-1.1x	-66%
Other income and expenses, net	4	13	21	5%	0%
Operating profit	48	162	317	-8%	0%
Finance income	1	5	8	-16%	-25%
Finance income from exchange difference	-	-	-	-100%	-100%
Finance costs	(35)	(118)	(236)	-2%	-3%
Finance costs from exchange difference	2	8	(19)	-	-
Net finance cost	(31)	(105)	(246)	1.3x	94%

Consolidated Statement of Income (2/2)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	2Q'26 (USD)	2Q'26	YTD 26	Δ 2Q'26 vs 2Q'25	Δ YTD 26 vs YTD 25
Share of profit of equity accounted investees	1	2	5	3%	-3%
Profit (loss) before tax	17	59	76	-55%	-61%
Income tax expense (benefit)	(8)	(26)	(33)	-45%	-54%
Net Income (Loss)	10	33	42	-61%	-65%
EBITDA					
Healthcare Services Mexico	22	75	147	-8%	7%
Healthcare Services Colombia	16	56	101	-4%	2%
Healthcare Services Peru & Oncosalud Peru	30	101	200	0%	-1%
- Healthcare Services Peru	10	34	65	2%	-13%
- Oncosalud Peru	19	66	135	0%	6%
Holding and eliminations	(2)	(8)	(10)		
Total EBITDA	65	223	438	-5%	2%
Adjusted EBITDA					
Healthcare Services Mexico	23	78	151	-11%	-10%
Healthcare Services Colombia	16	56	101	-4%	2%
Healthcare Services Peru & Oncosalud Peru	30	101	200	0%	-1%
- Healthcare Services Peru	10	35	65	2%	-14%
- Oncosalud Peru	20	67	135	0%	6%
Holding and eliminations	(2)	(8)	(9)		
Total Adjusted EBITDA	67	227	444	-6%	-4%
Adjusted EBITDA Margin					
Healthcare Services Mexico		25.9%	26.1%	-6.1 p.p.	-6.5 p.p.
Healthcare Services Colombia		13.1%	12.3%	-3.7 p.p.	-2.2 p.p.
Healthcare Services Peru & Oncosalud Peru		19.8%	19.8%	-1.5 p.p.	-1.9 p.p.
- Healthcare Services Peru		11.7%	11.3%	-0.9 p.p.	-2.9 p.p.
- Oncosalud Peru		21.0%	21.4%	-2.4 p.p.	-1.0 p.p.
Adjusted EBITDA Margin		18.4%	18.4%	-3.7 p.p.	-3.3 p.p.

Consolidated Cash Flow Statement

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

	YTD 26 (USD)	YTD 26	YTD 25	Δ YTD 26 vs YTD 25		YTD 26 (USD)	YTD 26	YTD 25	Δ YTD 26 vs YTD 25
Cash flows from operating activities					Cash flows from investing activities				
(Loss) profit for the period	12	42	122	(80)	Payment for accounts payables to former shareholder	(2)	(6)	(21)	15
Adjustments for:					Purchase of properties furniture and equipment	(11)	(37)	(48)	11
Depreciation	18	60	57	3	Purchase of intangibles	(8)	(27)	(34)	7
Depreciation of right-of-use assets	4	14	14	0	Dividends from equity-accounted investees	0	2	2	(1)
Amortization	12	42	38	4	Purchase of other investments, net of sales	8	29	(8)	37
(Reversal) Impairment of inventories	0	0	0	0	Proceeds from sale of property furniture and equipment	0	0	0	(0)
Equity-settled share-based payment transactions	1	5	5	(1)	Net cash used in investing activities	(12)	(41)	(109)	68
Gain (loss) on disposal of property furniture and equipment	0	0	0	(0)	Cash flows from financing activities				
(Reversal) loss for impairment of trade receivables	2	8	23	(15)	Proceeds from settlement of derivatives - interest rate swaps	(3)	(11)	(3)	(8)
Share of profit of equity-accounted investees	(1)	(5)	(5)	0	Proceeds from loans and borrowings	59	201	822	(621)
Technical provisions and other provisions	1	2	1	1	Payment for loans and borrowings	(73)	(250)	(785)	535
Finance income	(2)	(8)	(117)	108	Payment for lease liabilities	(6)	(21)	(22)	1
Finance costs	75	255	244	11	Penalty paid for debt prepayment	(0)	(0)	(0)	(0)
Tax expense	10	33	72	(38)	Payment for derivatives premiums	(4)	(15)	(15)	(0)
Net changes in assets and liabilities					Interest paid	(51)	(175)	(205)	30
Trade accounts receivable and other assets	(8)	(29)	(83)	55	Net cash used in financing activities	(80)	(271)	(209)	(63)
Inventories	7	25	7	19	Net (decrease) increase in cash and cash equivalents	38	129	(66)	195
Trade accounts payable and other accounts payable	15	52	(24)	77	Cash and cash equivalents at January 1	98	335	236	100
Provisions and employee benefits	(0)	(1)	(3)	2	Effect of movements in exchange rates on cash held	4	13	5	8
Insurance contract liabilities	3	11	1	10	Cash and cash equivalents at the end of the period	140	478	175	303
Cash generated from operating activities	149	507	351	156					
Income tax paid	(22)	(75)	(109)	34					
Interest received	2	8	9	(1)					
Net cash from operating activities	129	441	251	190					

Adjusted EBITDA and Adjusted EBITDA Margin reconciliation

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

Adjusted EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projects under construction, business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities, stock-based consideration and personnel non-recurring compensation.

Adjusted EBITDA Margin: is calculated as Adjusted EBITDA divided by total revenue from contracts with customers.

	2Q'26 (USD)	2Q'26	YTD 26	Δ 2Q'26 vs		Δ YTD 26 vs
				2Q'25	1Q'26	YTD 25
Revenues	363	1,238	2,416	13%	5%	13%
Profit (Loss) before Tax	17	59	76	-55%	259%	-61%
(+) Net Finance Cost	31	105	246	127%	-25%	94%
(+) Depreciation and Amortization	17	59	116	6%	2%	7%
(=) EBITDA	65	223	438	-5%	4%	2%
(+) Adjustments	1.2	4.0	6.1			
(a) Pre-operating expenses	0.0	0.2	0.4			
(b) Business development expenses	0.3	0.9	0.9			
(c) Stock-based consideration	0.9	2.9	4.9			
(d) Personnel non-recurring compensation	0.0	0.0	0.0			
(=) Adjusted EBITDA	67	227	444	-6%	5%	-4%
Adjusted EBITDA Margin		18.4%	18.4%	-3.7 p.p.	-0.1 p.p.	-3.3 p.p.

(a) Pre-operating expenses consist of legal and administrative expenses incurred in connection with medical facilities under construction, such as Clínica Chiclayo, costs relating to the Torre Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.

(b) Business development expenses consist of expenses incurred in connection with projects and payments to sellers to expand into new markets, including through greenfield projects and M&A activity.

(c) Stock-based consideration includes share-based payments plans for non-executive members of the Board of Directors and other Auna management including executives and employees.

(d) Personnel non-recurring compensation related to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the local and regional levels.

Notes: Considers an exchange rate of S/3.4100 to US\$1.00.

Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

For the three months ended June 30, 2026

	Healthcare Services Mexico	Healthcare Services Peru	Oncosalud Peru	Healthcare Services Colombia	Holding and eliminations	Consolidated Reportable Segments
Revenues	300	296	317	427	(103)	1,238
Profit (Loss) before Tax	7	20	53	46	(66)	59
(+) Net Finance Cost	45	4	3	(2)	56	105
(+) Depreciation and Amortization	23	11	10	12	3	59
(=) Segment EBITDA	75	34	66	56	(8)	223
(+) Adjustments	2.8	0.2	0.2	0.1	0.7	4.0
Pre-operating expenses	0.0	0.0	0.0	0.0	0.2	0.2
Business development expenses	0.9	0.0	0.0	0.0	0.0	0.9
Stock-based consideration	1.9	0.2	0.2	0.1	0.6	2.9
Personnel non-recurring compensation	0.0	0.0	0.0	0.0	0.0	0.0
(=) Segment Adjusted EBITDA	78	35	67	56	-8	227
Adjusted EBITDA Margin	25.9%	11.7%	21.0%	13.1%		18.4%

For the three months ended June 30, 2025

	Healthcare Services Mexico	Healthcare Services Peru	Oncosalud Peru	Healthcare Services Colombia	Holding and eliminations	Consolidated Reportable Segments
Revenues	274	269	286	346	(81)	1,094
Profit (Loss) before Tax	34	12	54	40	(8)	132
(+) Net Finance Cost	26	10	4	8	(1)	46
(+) Depreciation and Amortization	22	12	9	10	3	55
(=) Segment EBITDA	82	34	67	58	(6)	234
(+) Adjustments	5.7	0.2	0.2	0.0	1.0	7.2
Pre-operating expenses	0.0	0.0	0.0	0.0	0.5	0.5
Business development expenses	3.9	0.0	0.0	0.0	0.0	3.9
Stock-based consideration	1.7	0.2	0.2	0.0	0.6	2.6
Personnel non-recurring compensation	0.1	0.0	0.0	0.0	0.0	0.1
(=) Segment Adjusted EBITDA	88	34	67	58	(5)	241
Adjusted EBITDA Margin	32.0%	12.6%	23.4%	16.7%		22.1%

Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (continued)

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

Year to date June 30, 2026

	Healthcare Services Mexico	Healthcare Services Peru	Oncosalud Peru	Healthcare Services Colombia	Holding and eliminations	Consolidated Reportable Segments
Revenues	579	578	631	827	(199)	2,416
Profit (Loss) before Tax	11	33	101	65	(135)	76
(+) Net Finance Cost	90	11	13	14	120	246
(+) Depreciation and Amortization	46	21	21	23	5	116
(=) Segment EBITDA	147	65	135	101	(10)	438
(+) Adjustments	4.4	0.0	0.2	0.1	1.5	6.1
Pre-operating expenses	0.0	0.0	0.0	0.0	0.4	0.4
Business development expenses	0.9	0.0	0.0	0.0	0.0	0.9
Stock-based consideration	3.5	0.0	0.2	0.1	1.2	4.9
Personnel non-recurring compensation	0.0	0.0	0.0	0.0	0.0	0.0
(=) Segment Adjusted EBITDA	151	65	135	101	-9	444
Adjusted EBITDA Margin	26.1%	11.3%	21.4%	12.3%		18.4%

Year to date June 30, 2025

	Healthcare Services Mexico	Healthcare Services Peru	Oncosalud Peru	Healthcare Services Colombia	Holding and eliminations	Consolidated Reportable Segments
Revenues	517	532	567	685	(165)	2,136
Profit (Loss) before Tax	21	34	99	72	(32)	194
(+) Net Finance Cost	73	18	11	7	18	127
(+) Depreciation and Amortization	43	24	17	20	5	109
(=) Segment EBITDA	137	75	127	99	(8)	429
(+) Adjustments	31.6	0.3	0.3	0.1	1.9	34.3
Pre-operating expenses	0.0	0.0	0.0	0.0	0.7	0.7
Business development expenses	27.6	0.0	0.0	0.0	0.0	27.6
Stock-based consideration	3.4	0.3	0.3	0.1	1.2	5.3
Personnel non-recurring compensation	0.6	0.0	0.0	0.0	0.0	0.6
(=) Segment Adjusted EBITDA	168	76	127	99	-6	464
Adjusted EBITDA Margin	32.6%	14.2%	22.4%	14.5%		21.7%

Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

Consolidated Peru Adjusted EBITDA: is calculated by adding Healthcare Services Peru Segment Adjusted EBITDA plus Oncosalud Peru Segment Adjusted EBITDA.

Consolidated Peru Adjusted EBITDA margin: is calculated as Healthcare Services Peru Segment Adjusted EBITDA plus Oncosalud Peru Segment Adjusted EBITDA, divided by total revenues from Healthcare Services Peru Segment plus total revenues from Oncosalud Peru Segment.

Healthcare Services Peru and Oncosalud Peru Key Financial Metrics	2Q'26 (USD)	2Q'26	YTD 26	Δ 2Q'26 vs 2Q'25	Δ 2Q'26 vs 1Q'26	Δ YTD 26 vs YTD 25
Consolidated Revenue	150	512	1,012	8%	2%	8%
Healthcare Services Peru	87	296	578	10%	5%	8%
Oncosalud Peru	93	317	631	11%	1%	11%
Holding and Eliminations (*)		(101)	(196)	25%	6%	19%
Consolidated Peru Adjusted EBITDA	30	101	200	0%	2%	-1%
Healthcare Services Peru	10	35	65	2%	13%	-14%
Oncosalud Peru	20	67	135	0%	-2%	6%
Consolidated Peru Adj. EBITDA margin %		19.8%	19.8%	-1.5 p.p.	0.0 p.p.	-1.9 p.p.
Healthcare Services Peru		11.7%	11.3%	-0.9 p.p.	0.8 p.p.	-2.9 p.p.
Oncosalud Peru		21.0%	21.4%	-2.4 p.p.	-0.8 p.p.	-1.0 p.p.

(*) Relates to intersegment revenue elimination.

Adjusted Net Income reconciliation

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

Adjusted Net Income: is calculated as profit (loss) for the period plus adjustments as described below.

	2Q'26 (USD)	2Q'26	2Q'25	YTD 26	YTD 25
Net Income (Loss)	10	33	84	42	122
(a) Pre-operating expenses	0.0	0.2	0.5	0.4	0.7
(b) Business development expenses	0.3	0.9	3.9	0.9	27.6
(c) Stock-based consideration	0.9	2.9	2.6	4.9	5.3
(d) Personnel non-recurring compensation	0.0	0.0	0.1	0.0	0.6
(e) Non-cash and non-recurring financial costs	1.6	5.5	0.0	10.8	0.0
(f) Allocated tax effects	(0.5)	(1.8)	(2.6)	(2.7)	(13.0)
(=) Adjusted Net Income	12	40	89	56	143

(a) Pre-operating expenses consist of legal and administrative expenses incurred in connection with medical facilities under construction, such as Clínica Chiclayo, costs relating to the Centro Ambulatorio Trecca PPP and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.

(b) Business development expenses consist of expenses incurred in connection with projects and payments to sellers to expand into new markets, including through greenfield projects and M&A activity.

(c) Stock-based consideration includes share-based payments plans for non-executive members of the Board of Directors and other Auna management including executives and employees.

(d) Personnel non-recurring compensation related to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the local and regional levels.

(e) Non-cash and non-recurring financial costs include: 1) non-cash effects related to the accounting impact of changes in the fair value of the liability for mandatory purchase of shares from IMAT; and 2) withholding tax expenses associated with financing and refinancing activities.

(f) Allocated tax effects neutralize the tax shield that the items considered as adjustment have generated in the taxable profit.

Notes: Considers an exchange rate of S/3.4100 to US\$1.00.

Free Cash Flow

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

Free Cash Flow: is calculated by adding Net Cash Flows from Operations and Net Cash Flows used in Investing activities.

	Jun-25	Jun-26
Cash generated from operating activities	351	507
(-) Income tax	109	75
(+) Interest received	9	8
Net cash from operating activities	251	441
Net cash used in investing activities	(109)	(41)
Free Cash Flow	143	400

Adjusted Basic and Diluted Earnings per Share

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

Adjusted Basic and Diluted Earnings per Share: Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Income of the Company by the weighted average number of basic and diluted shares outstanding during the period, which excludes treasury shares.

	2Q'26 (USD)	2Q'26	2Q'25	YTD 26	YTD 25
Net Income (Loss)	10	33	84	42	122
Income (Loss) attributable to Owner of the company	9	29	82	36	117
Weighted average number of basic and diluted shares at June 30		74.2	74.2	74.2	74.2
Basic and diluted earnings per share	0.12	0.40	1.10	0.48	1.58
Adjusted Net Income (Loss)	12	40	89	56	143
Income (Loss) attributable to owners of Adjusted Net Income	11	37	87	50	139
Weighted average number of basic and diluted shares at June 30		74.2	74.2	74.2	74.2
Adjusted Basic and Diluted Earnings per Share	0.15	0.50	1.17	0.68	1.87

Notes: Considers an exchange rate of S/3.4100 to US\$1.00.

Net Debt reconciliation

(Figures in millions of Soles, unless expressed otherwise)

Net Debt: We calculate Net Debt as Gross Debt minus Cash and cash equivalents.

	Jun-25	Dec-25	Jun-26
(+) Loans and borrowings	3,574	3,533	3,606
<i>Short term debt</i>	598	316	399
<i>Long term debt</i>	2,976	3,216	3,207
(+) Lease Liabilities	129	124	124
Gross Debt	3,702	3,656	3,730
(-) Cash and cash equivalents	175	335	478
Net Debt	3,528	3,321	3,252

Leverage Ratio reconciliation

(Figures in millions of Soles, unless expressed otherwise)

Leverage Ratio: is calculated as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Last twelve months Adjusted EBITDA.

Adjusted Last Twelve Month (“LTM”) EBITDA: is calculated by adding the last four quarters beginning with the corresponding period.

	Jun-25	Dec-25	Jun-26
Current and non-current loans & borrowings	3,574	3,533	3,606
Current and non-current lease liabilities	129	124	124
Cash and cash equivalents	175	335	478
Net Debt	3,528	3,321	3,252
Adjusted LTM EBITDA	968	917	897
Leverage Ratio	3.6x	3.6x	3.6x

Key Operational Metrics – Oncosalud Peru & Healthcare Services

	2Q'26	YTD 26	Δ 2Q'26 vs 2Q'25	Δ YTD 26 vs YTD 25
Oncosalud Peru				
Plan memberships ⁽¹⁾⁽²⁾	1,472,019	1,472,019	6%	6%
Average monthly revenue per plan member ⁽³⁾	S/ 63.35	S/ 62.79	4%	4%
Preventive check-ups ⁽⁴⁾	26,105	56,799	-16%	-12%
Patients treated ⁽⁵⁾	50,991	97,498	27%	25%
Medical loss ratio ⁽⁶⁾	55.9%	55.9%	1.0 p.p	1.0 p.p
Healthcare Services				
Total bed capacity ⁽¹⁾⁽⁷⁾	2,228	2,228	0%	0%
Protected Lives ⁽⁸⁾	3,143,694	3,143,694	26%	26%
Surgeries ⁽⁹⁾	21,912	43,522	5%	5%
Emergency treatments ⁽¹⁰⁾	97,857	189,283	7%	9%
Chemotherapies & Radiotherapies ⁽¹¹⁾	57,579	111,731	15%	9%
Total number of days hospitalized ⁽¹²⁾	135,107	267,373	5%	4%
Operating capacity utilization ⁽¹³⁾	76.6%	76.2%	5.8 p.p	5.2 p.p
Total capacity utilization ⁽¹⁴⁾	66.6%	66.3%	2.8 p.p	2.3 p.p

1) As of period end.

2) As reported to the National Superintendence of Health Susalud. Includes Oncology plans and Health plans. Includes active plan members and inactive members. Inactive members are defined as those plan members that have not paid monthly fees due for up to three months. As of June 30th, 2026, we had 1,362,625 active members and 109,394 inactive members.

3) Total revenue for the period corresponding to insurance revenue in the Oncosalud Peru segment divided by the average number of plan members during the period, divided by the number of months in the period.

4) Preventive check ups consider Oncosalud and Healthcare plan check ups, including for Auna Corporate plans, receiving check ups at the Centro de Bienestar Ambulatorio – CBA (Wellness Center) in Lima and at other facilities in Peru.

5) Number of individual plan members in Oncosalud and Healthcare plans, including Auna Corporate plans, receiving treatment during the period in Peru. Each plan member is counted once for a trimester, however, might have received multiple instances of treatment throughout the year.

6) MLR is calculated as (i) claims for medical treatment generated by our prepaid oncology and general healthcare plans plus (ii) technical reserves relating to plan members treated pursuant to such plans, whether at our facilities or third-party facilities, divided by revenue generated by our prepaid oncology and general healthcare plans.

7) Includes all beds within the Healthcare Network and excludes 109 Oncology beds.

8) Insured population assigned to Auna under risk-sharing agreements in Colombia.

9) Number of surgeries includes surgeries outpatient surgeries and cesarean sections

10) Emergency care includes the number of visits in the emergency room and may include several visits per patient.

11) Intravenous chemotherapy and radiotherapy infusions in both inpatient and outpatient care; excludes oral treatments. In Peru, includes sessions across the Healthcare Services Network and Oncosalud Segments.

12) Total number of days during which any of Auna's beds were occupied by a hospitalized patient during the period, including ICU.

13) Operating capacity utilization (Occupancy) is calculated as (i) (x) total number of days in which any of our beds had a hospitalized patient during the period divided by (y) total number of operating beds, times (ii) total number of days during the period.

14) Total capacity utilization (Occupancy) is calculated as (i) (x) total number of days in which any of our beds had a hospitalized patient during the period divided by (y) total number of beds, times (ii) total number of days during the period.

Trends in Key Financial Metrics

(Figures in millions of Soles, unless expressed otherwise)

	2Q'24	3Q'24	4Q'24	1Q'25	2Q'25	3Q'25	4Q'25	1Q'26	2Q'26
Revenue									
Oncosalud Peru	269	273	276	281	286	294	304	314	317
Healthcare Services Peru	255	255	245	263	269	279	273	281	296
Healthcare Services Colombia	378	363	353	339	346	369	387	400	427
Healthcare Services Mexico	302	316	268	243	274	264	258	279	300
Holding and eliminations	(83)	(80)	(79)	(84)	(81)	(88)	(89)	(96)	(103)
Total revenue from contracts with customers	1,120	1,127	1,063	1,042	1,094	1,117	1,133	1,178	1,238
Cost of sales and services	(693)	(677)	(629)	(660)	(660)	(698)	(704)	(747)	(796)
Gross profit	427	449	434	382	434	419	429	431	442
Selling expenses	(48)	(55)	(42)	(54)	(54)	(59)	(54)	(62)	(62)
Administrative expenses	(202)	(195)	(201)	(182)	(208)	(200)	(222)	(214)	(232)
Impairment losses on trade receivables	(3)	(25)	(13)	(16)	(8)	(5)	(19)	(9)	0
Other expenses	0	0	(2)	0	0	0	0	0	0
Other income	8	54	14	9	12	11	11	9	13
Operating profit	183	229	190	139	176	166	144	155	162
Finance income	7	6	7	6	5	4	6	4	5
Finance income from exchange difference	0	28	(31)	37	68	40	48	0	0
Finance costs	(139)	(138)	(138)	(123)	(120)	(116)	(292)	(118)	(118)
Finance costs from exchange difference	(49)	0	8	0	0	0	0	(26)	8
Net finance cost	(182)	(103)	(155)	(80)	(46)	(72)	(238)	(141)	(105)
Share of profit of equity-accounted investees	2	2	2	3	2	3	2	3	2
Profit (loss) before tax	3	127	37	62	132	97	(91)	16	59
Income tax (expense) benefit	5	(27)	(13)	(24)	(48)	(44)	27	(7)	(26)
Net Income	8	101	24	38	84	53	(64)	9	33
EBITDA	241	286	244	195	234	226	203	215	223
EBITDA Adjustments									
Net Income	8	101	24	38	84	53	(64)	9	33
Income tax expense	(5)	27	13	24	48	44	(27)	7	26
Net finance cost	182	103	155	80	46	72	238	141	105
Depreciation and amortization	56	55	52	53	55	57	56	57	59
(a) Pre-operating expenses	2	0	0	0	0	(0)	0	0	0
(b) Business development expenses	1	(44)	3	24	4	4	10	0	1
(c) Change in fair value of earn-out liabilities	0	0	0	0	0	0	0	0	0
(d) Stock-based consideration	0	6	3	3	3	3	3	2	3
(e) Personnel non-recurring compensation	4	2	5	0	0	0	5	0	0
(f) Change in fair value of investment properties	0	0	0	0	0	0	0	0	0
Adjusted EBITDA	248	250	254	222	241	232	220	217	227



Investor Relations

contact@aunainvestors.com
www.aunainvestors.com